Novartis Brings Advanced Cancer Treatment Manufacturing to Florida

Novartis announced plans to build a state-of-the-art radioligand therapy manufacturing facility in Winter Park, Florida, marking the company’s fourth RLT production site in the United States. The 35,000-square-foot facility represents part of Novartis’ $23 billion US investment and is expected to come online by 2029.

The new facility will strengthen the company’s ability to deliver time-sensitive cancer treatments to patients across the southeastern United States. Radioligand therapy pairs tumor-targeting molecules with therapeutic radioisotopes, delivering radiation directly to cancer cells while minimizing damage to healthy tissue. Each dose is individually prepared and highly time-sensitive, making proximity to treatment centers critical for patient care.

Manufacturing Network Expands Across the US

Novartis currently operates RLT facilities in Indiana and New Jersey and recently completed a new California site in November. The company plans to build a fifth US location in the coming years. This network supports Novartis’ position as the only company with two FDA-approved RLT treatments and an extensive pipeline across multiple cancer types, including prostate, breast, colon, lung, brain, and pancreatic cancers.

According to the company, its current delivery performance exceeds 99% of doses administered on the planned day. The Florida facility will help maintain this reliability as demand for RLT treatments continues to grow.

Florida’s Growing Life Sciences Sector

Florida’s investment in life sciences education and skilled workforce development played a role in Novartis’ site selection. The state ranks second nationally in both pharmaceutical manufacturing and medical device technology, according to Florida’s Department of Commerce.

“Florida has steadily invested in higher education for life sciences and technology, helping to build the next generation of leaders critical to driving forward advanced manufacturing,” said Florida Secretary of Commerce J. Alex Kelly. The state’s regulatory environment and focus on pharmaceutical innovation position it as an attractive location for advanced manufacturing operations.

What This Means for Manufacturing Operations

For manufacturing leaders, Novartis’ investment demonstrates how specialized production requirements drive facility location decisions. RLT manufacturing demands specialized talent, precise timing, and proximity to end users. These factors mirror challenges many manufacturers face when planning capital investments and facility expansions.

The pharmaceutical sector’s growth in Florida reflects broader manufacturing trends showing the Southeast’s increasing importance as a production hub. According to the US Bureau of Economic Analysis, Florida’s manufacturing sector contributed $38.6 billion to the state’s GDP in 2024, highlighting the economic impact of advanced manufacturing operations.

Financial and Strategic Considerations

Major facility investments like Novartis’ Florida plant require careful analysis of workforce availability, supply chain logistics, and regulatory environment. For manufacturers evaluating expansion opportunities, understanding local incentives, talent pipelines, and infrastructure becomes essential to long-term success.

The five-year timeline for Novartis’ US RLT network buildout illustrates the extended planning horizon required for specialized manufacturing facilities. Similar considerations apply to manufacturers assessing new equipment, technology adoption, or geographic expansion.

Life Sciences Manufacturing Growth in FL

As life sciences manufacturing grows in Florida and across the Southeast, opportunities emerge for suppliers, logistics providers, and related industries. Pharmaceutical manufacturing employment grew 8% nationally from 2022 to 2024, indicating sustained sector growth.

Make operational decisions backed by data, not guesswork. Partner with our advisors to gain better visibility into job costing, production performance, and cash flow.

All content provided in this article is for informational purposes only. Matters discussed in this article are subject to change. For up-to-date information on this subject please contact a James Moore professional. James Moore will not be held responsible for any claim, loss, damage or inconvenience caused as a result of any information within these pages or any information accessed through this site.